loader image

References

  1. Trelstar® (triptorelin pamoate for injectable suspension) [prescribing information]. Wayne, PA: Verity Pharmaceuticals, Inc. October 2020.
  2. Heyns CF, Simonin M-P, Grosgurin P, Schall R, Porchet HC. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU International. 2003;92:226-231
  3. Bowers CY, Folkers K. Gonadotropin-releasing hormone (GnRH), GnRH superagonists, and GnRH antagonists. In: Munson PL, Mueller RA, Breese GR, eds. Principles of Pharmacology Basics Concepts & Clinical Applications. New York, NY: Chapman & Hall:1995:887-985.
  4. Morgan K, Leighton SP, Millar RP. Probing the GnRH receptor agonist binding site identifies methylated triptorelin as a new anti-proliferative agent. J Mol Biochem. 2012;1:86-98.
  5. Crawford ED, Twardowski PW, Concepcion RS, et al. The impact of late luteinizing hormone-releasing hormone agonist dosing on testosterone suppression in patients with prostate cancer: An analysis of United States clinical data. J Urol. 2020; 203:743-50.
  6. Data on file, Verity Pharmaceuticals, Inc.
  7. Millar RP, Troskie BE, Flanagan CA. Comparative receptor binding affinity and inositol phosphate production potency of D-Leu6 and D-Trp6 GnRH agonist on COS-1 cells transfected with the human GnRH receptor. XII International Congress of Comparative Endocrinology. 1997;559-562.
  8. Harrison GS, et al. Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocrine-Related Cancer. 2004; 11(4):725-48.
  9. Teillac P, Heyns CF, Kaisary AV, Bouchot O, Blumberg J. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer. Horm Res. 2004;62:252-258.
  10. Bertaglia V, Tucci M, Fiori C et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 2013;11:325-30
  11. Dason S, Allard CB, Tong J, et al. Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. Can Urol Assoc J 2013;7:E263-7.
  12. Kawakami J, Morales A. Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists. Can Urol Assoc J 2013;7:E226-30.
  13. Morote J, et al. Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy. J Urol 2007;178:1290-1295
  14. van der Sluis TM, et al. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol 2012 May;187(5):1601-6.
  15. Crawford ED, Heidenreich A, Lawrentschuk N, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer and Prostatic Diseases 2018;https://doi.org/10.1038/s41391-018-0079-0

Order Trelstar from AndaMEDS

Trelstar can be ordered directly from our national specialty distributor, AndaMEDS, which provides next business day delivery and other convenient benefits. Call AndaMEDS at 1.855.468.5649, ext.74453.

 

If you already have a Trelstar account with AndaMEDS®, please click here or register at www.andameds.com.

Thank you for visiting.

You are now leaving a Verity website. A link to a non-Verity website does not constitute an endorsement of the products or services offered by the non-Verity website, and Verity is not responsible for the content of any non-Verity website.

Healthcare Professionals

The information contained in this website is intended for US Healthcare professionals only.